ObjectiveTo systematically review the effectiveness and safety of domestic tirofiban for Chinese population with non ST-elevation acute coronary syndromes (NSTE-ACS) in non-interventional therapy. MethodsWe searched databases including The Cochrane Library (Issue 11, 2013), PubMed, EMbase, CBM, CNKI, VIP and WanFang Data from 1994 to 2014 to collect randomized controlled trials (RCTs) about domestic tirofiban for NSTE-ACS patients in non-interventional therapy. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality of included studies. Meta-analysis was then conducted using RevMan 5.2 software. ResultsA total of 23 RCTs were enrolled involving 2 425 patients. The results of meta-analysis showed that:a) the effectiveness of tirofiban in the trial group was significantly better than that in the control group (OR=3.62, 95%CI 2.33 to 5.63, P<0.000 01); b) ST segment down improvement in the trial group was better than that in the control group (WMD=0.39, 95%CI 0.30 to 0.49, P<0.000 01); c) improvement of platelet aggregation in the trial group was better than that in the control group (WMD=27.89, 95%CI 25.45 to 30.34, P<0.000 01); d) the incidences of cardiovascular events of composite endpoints in the trial group were lower than that in the control group (during 36 h:OR=0.20, 95%CI 0.12 to 0.31, P<0.000 01; and after 30 days:OR=0.31, 95%CI 0.23 to 0.42, P<0.000 01); and e) the incidence rate of bleeding in the trial group was higher than that in the control group (OR=1.53, 95%CI 1.09 to 2.15, P=0.02). ConclusionCompared with routine drugs used alone, tirofiban has better therapeutic effects in non-interventional therapy for Chinese population with NSTE-ACS, but the incidence of bleeding is relatively high.
ObjectiveTo systematically review the association between ORMDL3 gene rs7216389 polymorphism and the susceptibility to asthma among Chinese population. MethodsSuch databases as PubMed, EMbase, The Cochrane Library (Issue 8, 2014), CBM, CNKI, VIP and WanFang Data were systemically searched to collect casecontrol studies published to August 2013. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and evaluated methodological quality of included studies. Meta-analysis was then performed using RevMan 5.2 software. Stata 11.0 software were used for publication bias evaluation. ResultsA total of 7 case-control studies were included, which involved 1 711 cases and 1 763 controls. The results of meta-analysis showed that, ORMDL3 gene rs7216389 polymorphism was associated with the susceptibility to asthma among Chinese population (OR=0.71, 95%CI 0.62 to 0.81, P<0.000 01). In the subgroup analysis by age, ORMDL3 gene rs7216389 polymorphism was associated with the susceptibility to adult asthma (OR=0.71, 95%CI 0.61 to 0.83, P<0.000 1) and children asthma (OR=0.69, 95%CI 0.52 to 0.90, P=0.006). ConclusionORMDL3 gene rs7216389 polymorphism is a risk factor of adult and children asthma among Chinese population.